Innovative treatment strategy for intractable gastroenterological cancer by control of DNA double strand repair pathway

控制DNA双链修复通路治疗难治性胃肠癌的创新策略

基本信息

批准号：
22591457
负责人：
SAEKI Hiroshi
金额：
$ 2.91万
依托单位：
Kyushu University (2011-2012)Department of Clinical Research, National Hospital Organization National Kyushu Cancer Center (2010)
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2010
资助国家：
日本
起止时间：
2010 至 2012
项目状态：
已结题

项目摘要

Patients and Method. 1) One hundred sixty-eight patients with clinical Stage II-III (cStageII-III) ESCC were classified into two groups consisting of 76 who received NACRT followed by esophagectomy and 92 patients who received surgery alone. The prognosis and incidence of postoperative complications were retrospectively compared between the two groups. The pathological response to NACRT as well as the patientprognosis were also analyzed for the NACRT group patients. 2) The expression of Rad51 was investigated in pretreatment biopsy specimens in 41 ESCC cases who underwent surgery after NACRT, and the findings were compared with the pathological response to NACRT. Results. 1) The 5-year survival rate was 47.7% in the surgery alone group and 56.5% in the NACRT group, and the difference was not a statistically 機関番号：17102研究種目：基盤研究（Ｃ）研究期間：2010～2012課題番号：22591457研究課題名（和文） DNA2重鎖切断修復機構の制御による難治性消化器癌に対する革新的治療戦略研究課題名（英文） Innovative treatment strategy for intractable gastroenterological cancer by control of DNA double strand repair pathway研究代表者佐伯浩司（SAEKI HIROSHI）九州大学・大学病院・助教研究者番号：80325448significant (P=0.4831). However, the 5-year survival rates of patients in whom NACRT was Grade 3 (markedly effective), was obviously better than that of the other patients (Grade0/1 - ineffective/slightly effective: 36.9%, Grade 2 - moderately effective: 53.8%, Grade 3 - markedly effective: 100%). The incidence of postoperative complications was 31.5% in the surgery alone group and 40.8% in the NACRT group, and the difference was not a statistically significant (P=0.2121). 2) Grade 3 was more frequently observed in Rad51-negative cases (n=13) than Rad51-positive cases (n=28; 71.4% vs. 28.6%, P=0.0239). Conclusions. The pathological complete response of NACRT is critical for improving the survival of patients with cStageII-III ESCC. The Rad51 expression in pretreatment biopsy specimens was therefore suggested to be a useful predictive factor for the response to NACRT.

患者和方法。 1）将一百六十八名II-III（CSTAGE II-III）ESCC患者分为两组，由76例接受NACRT，然后接受食管切除术和92例仅接受手术的患者。在两组之间进行了回顾性比较术后并发症的预后和发生率。还分析了NACRT组患者的患者预见。 2）在41例ESCC病例中研究了RAD51的表达，他们在NACRT后接受了手术，并将发现与患者对NACRT的反应进行了比较。结果。 1) The 5-year survival rate was 47.7% in the surgery alone group and 56.5% in the NACRT group, and the difference was not a statistically Institution number: 17102 Research category: Basic research (C) Research period: 2010-2012 Symptom number: 22591457 Research topic name (Japanese) Innovative treatment strategy for intractable gastroenterological cancer by control of DNA double strand repair pathway Innovative treatment strategy for通过控制DNA双链修复途径研究人员编号：80325448Sixtimant（p = 0.4831），可顽固的胃肠癌癌症。但是，NACRT年龄3级的患者的5年生存率显然比其他患者（级/1级无效/有效）好：36.9％，2级，中度有效：53.8％，53.8％，3级，显着有效：100％）。单独手术组的术后并发症发生31.5％，在NACRT组中为40.8％，差异并不具有统计学意义（p = 0.2121）。 2）在RAD51阴性病例中比Rad51阳性病例（n = 28; 71.4％vs. 28.6％，p = 0.0239）更频繁地观察到3级。结论。 NACRT的患者学完全反应对于改善CSTAGEII-III ESCC患者的存活至关重要。因此，认为预处理活检标本中的RAD51表达是对NACRT反应的有用预测因素。